Tuesday, 20 October 2015
AstraZeneca today announced the opening of its new state-of-the-art manufacturing and packaging facility in Kaluga, Russia, dedicated to the local supply of innovative medicines.
In 2011 AstraZeneca was one of the first multinational pharmaceutical companies to announce plans to invest in the construction of a dedicated manufacturing facility in Russia. Four years on, the Company has invested $224m in the development, which is the largest foreign investment in the construction of a new pharmaceutical facility in the country.
Commenting from Russia on the opening of the Kaluga facility, Pascal Soriot, Chief Executive Officer, said: “Our new dedicated production facility will support our efforts to bring innovative medicines from our exciting pipeline to patients in Russia. This opening builds on our investments in clinical research and scientific collaborations in this important country and serves to reinforce our long term commitment to Russia.”
Commercial production will begin early next year and will focus on final-stage manufacturing, packaging and quality control. The site will become fully operational in 2017 and will produce around 40 million packs and 850 million tablets of some 30 innovative medicines every year. This represents more than 60% of AstraZeneca’s medicines marketed in Russia to treat diseases across the Company’s therapy areas.
The new facility adds to the expansion of AstraZeneca’s global manufacturing capabilities to support the company’s expanding portfolio of medicines and growing demand, following on from the planned biologics manufacturing investments in Sweden (announced in May 2015), the acquisition of a new site in Boulder, Colorado, US (announced in September 2015) and the expansion in Frederick, Maryland, US (announced in November 2014).
NOTES TO EDITORS
About AstraZeneca in Russia
Since establishing its presence in 1993, AstraZeneca has steadily built its capabilities in Russia and now employs more than 1,400 people working across commercial, manufacturing, scientific and clinical research and enabling functions. Around 50 of AstraZeneca’s innovative medicines are licensed for sale in Russia.
As a key market for the Group’s emerging markets ambitions, achieving continued growth is a strategic priority for AstraZeneca in Russia where the company achieved Product Sales of more than $200m in 2014, supported by continued investments.
AstraZeneca makes a significant contribution to the development of the innovative healthcare sector in Russia and was one of the first multinational pharmaceutical companies to invest in the construction of a full-cycle manufacturing facility dedicated to local production. AstraZeneca also invests in clinical research and scientific collaborations in Russia. In 2015, we conducted 27 clinical trials in Russia involving more than 5,000 patients, and have several important collaborations with leading academic and research institutions. As a socially responsible company, AstraZeneca Russia implements initiatives focused on the prevention of non-communicable diseases among young people through the Young Health Programme.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
CONTACTS
Media Enquiries
| Esra Erkal-Paler | (UK/Global) | +44 20 7604 8030 |
| Vanessa Rhodes | (UK/Global) | +44 20 7604 8037 |
| Ayesha Bharmal | (UK/Global) | +44 20 7604 8034 |
| Karen Birmingham | (UK/Global) | +44 20 7604 8120 |
| Jacob Lund | (Sweden) | +46 8 553 260 20 |
| Michele Meixell | US | +1 302 885 2677 |
Investor Enquiries
UK
Name |
Area | Phone Number | Mobile Phone Number |
|---|---|---|---|
| Thomas Kudsk Larsen | +44 20 7604 8199 | +44 7818 524185 | |
| Eugenia Litz | RIA | +44 20 7604 8233 | +44 7884 735627 |
| Nick Stone | CVMD | +44 17 6326 3994 | +44 7717 618834 |
| Craig Marks | ING | +44 20 7604 8591 | +44 7881 615764 |
| Christer Gruvris | +44 20 7604 8126 | +44 7827 836825 |
US
Name |
Area | Phone Number | Mobile Phone Number |
|---|---|---|---|
| Lindsey Trickett | Oncology, ING | +1 301 398 5118 | +1 240 543 7970 |
| Mitch Chan | Oncology | +1 301 398 1849 | +1 240 477 3771 |
| Dial / Toll-Free | +1 301 398 3251 | +1 866 381 7277 |
Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease, ING - Infection, Neuroscience and Gastrointestinal